

2909-121 – First in Man: Coronary Sinus Narrowing With a Reducer Stent: A Possible Alternative Percutaneous Treatment for Patients With Refractory Angina—*Shmuel Banai, *Gad Keren, Horst Sievert, Ashok Seth, *Shmuel Ben Muvhar, Ajay M. Naik, Aharon Medina, Praveen Chandra, Hethal Shah, Keyur H. Parikh, Sourasky Tel Aviv Medical Center, Tel Aviv, Israel

2909-122 – Clinical Benefit of Pretreatment With High Dose of Clopidogrel Before Percutaneous Coronary Intervention Is Associated With Lower Procedural Levels of P-Selectin: Results From the ARMYDRA-2 (Antiplatelet therapy for Reduction of MYocardial Damage During Angioplasty) Select Substudy—Giuseppe Patti, Massimo Chello, Diego Colonna, Andrea D'Ambrosio, Vincenzo Pasceri, Leonardo Lassandro Pepe, Laura Gatto, Fabio Cacciapaglia, Giordano Dicuonzo, Elvio Covino, Germano Di Sciascio, Campus Bio-Medico University, Rome, Italy

LIVE CASES

2102

**Live Case Transmission
Session II**

Sunday, March 12, 2006, 2:00 p.m.–3:30 p.m.
*Georgia World Congress Center, Georgia Ballroom
Clinique Pasteur (France)
Saint Joseph's Hospital of Atlanta (Georgia)*

Master Victor E. Corrigan,
Interventionalists: Atlanta, GA
*Jean Fajadet, Toulouse,
France
Bruno Farah, Toulouse,
France
William Knapp, Atlanta, GA
*Stephen R. Ramee,
New Orleans, LA
Charles A. Simonton,
Charlotte, NC

Moderator: David R. Holmes, Jr.,
Rochester, MN

E-Moderators: Samir R. Kapadia, Cleveland,
OH
Christopher J. White,
New Orleans, LA

Overall *Barry D. Rutherford,
Coordinator: Kansas City, MO

Panelists: *Robert M. Bersin, Seattle, WA
*Maurice Buchbinder, La Jolla, CA
*James B. Hermiller, Jr.,
Indianapolis, IN
*David E. Kandzari, Chapel Hill, NC
Jean Marco, Toulouse, France
*John A. Ormiston, Auckland,
New Zealand
*Gary S. Roubin, New York, NY
Sigmund Silber, Munich, Germany
*Mark A. Turco, Takoma Park, MD

Objectives: At the conclusion of this session, participants will be able to: 1) understand characteristics of carotid artery lesions suitable for stenting; 2) understand specific technical approaches to carotid stenting; and 3) understand techniques for peripheral vascular stenting.

EXPERTS

2203

**Drug-Eluting Stent
Misadventures**

Sunday, March 12, 2006, 2:00 p.m.–3:00 p.m.
Georgia World Congress Center, Room C201

Chair: *Paul S. Teirstein, La Jolla, CA

Case Presenter: *Elizabeth M. Holper,
Chicago, IL

Panelists: Daniel H. Berrocal, Buenos Aires,
Argentina
*James P. Zidar, Cary, NC

Objectives: At the conclusion of this session, participants will be able to do one or more of the following: 1) state new approaches to the ongoing management of cardiovascular states or conditions; 2) select ideas to implement in their practice; and/or 3) relate research outcomes to the practice of cardiology.

day real-world practice; and 4) discuss the pros and cons of thrombin inhibitors and clopidogrel as foundation therapy for percutaneous coronary intervention.

8:00 – Clopidogrel: Loading Doses, Duration of Therapy—Germano DiSciascio, Rome, Italy

8:10 – Novel Oral Antiplatelet Therapies—*Elliott M. Antman, Boston, MA

8:20 – Glycoprotein IIb/IIIa and Acute Coronary Syndrome: Has It Been Replaced?—*Eric D. Peterson, Durham, NC

8:30 – Glycoprotein IIb/IIIa Inhibitors and the Real World: Outcomes and Economics—*David J. Cohen, Boston, MA

8:40 – Antiplatelet Resistance: Is It Real?—Paul A. Gurbel, Baltimore, MD

8:50 – Clopidogrel and Surgical Bleeding—TBD

Adjunctive Pharmacologic Therapy for Percutaneous Coronary Intervention: Thrombip Inhibitors and Plavix Are Enough

9:00 – Opening Arguments/Rebuttal, Protagonist—*Frederick Feit, New York, NY

9:25 – Opening Arguments/Rebuttal, Antagonist—*James E. Tcheng, Durham, NC

9:50 – Rebuttal, Protagonist

9:55 – Rebuttal, Antagonist

CORE 2706 Percutaneous Coronary Intervention Guidelines 

Tuesday, March 14, 2006, 8:00 a.m.–10:00 a.m.
Georgia World Congress Center, Room C208

Co-Chairs: *George D. Dangas, New York, NY
*Barry F. Uretsky, Galveston, TX

Objectives: At the conclusion of this session, attendees will be able to: 1) understand percutaneous coronary intervention guidelines for various clinical settings in patients with myocardial infarction; 2) understand the

advantages and limitations of percutaneous coronary intervention without surgical backup; and 3) outline the post-percutaneous coronary intervention clinical care.

8:00 – European Percutaneous Coronary Intervention Guidelines—Sigmund A. Silber, Munich, Germany

8:15 – Primary Percutaneous Coronary Intervention for Segment Elevation Myocardial Infarction—*Sidney C. Smith, Jr., Chapel Hill, NC

8:30 – Invasive Management of Non ST Segment Elevation Myocardial Infarction—*Adnan Kastrati, Munich, Germany

8:45 – Routine Percutaneous Coronary Intervention After Acute Myocardial Infarction—Eric R. Bates, Ann Arbor, MI

9:00 – Elective Percutaneous Coronary Intervention Without On-Site Surgery—Thomas P. Wharton, Jr., Exeter, NH

9:15 – Long-Term Management of Patient After Percutaneous Coronary Intervention—Donald E. Cutlip, Boston, MA

9:30 – Class II Recommendations: The Gray Zones—Alan C. Yeung, Palo Alto, CA

9:45 – Questions and Answers

CORE 2707 Complex Coronary Intervention: State of the Art 

Tuesday, March 14, 2006, 8:00 a.m.–10:00 a.m.
Georgia World Congress Center, Room C206

Co-Chairs: Steven R. Bailey, San Antonio, TX
*Harry R. Phillips, Durham, NC

Objectives: At the conclusion of this session, attendees will be able to: 1) understand when and how to apply new devices and techniques for the interventional management of complex lesions; 2) describe the roles of medical, intravascular and surgical therapies for difficult coronary revascularizations; and 3) review how to optimize acute and long-term outcomes in patients with complex coronary lesions.



**i2
summit
2006**

innovation in intervention

**American College of Cardiology
in co-sponsorship with SCAI**

FINAL PROGRAM
MARCH 11 - 14, 2006
ATLANTA, GEORGIA